Business Wire

Is Wanderlust in Our DNA? Curio Collection by Hilton Launches The Curious Gene Program

Jaa

Are you born curious? This fall, Curio Collection by Hilton™ – one of Hilton’s (NYSE: HLT) 14 market-leading brands – is helping travelers find out by digging into their love of exploration. Through consumer research, the brand discovered that people are seeking unique experiences as an integral aspect of their travel. With that insight, and with curiosity at the core of the brand name, Curio Collection turned to science to sponsor the DNA testing of approximately 30 avid travelers who love sharing their journeys with their social media followers. The goal was to determine if they have the DRD4-7R gene, better known as the “wanderlust gene,” in an effort to understand our innate desire to travel. Today, the collection brand launches an “Are You Curious?” social media quiz, to allow everyone to put their curiosity to the test.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170928005454/en/

“A curious traveler is someone whose desire for one-of-a-kind discoveries draws them to distinctive hotels that are an essential part of their travel experience,” said Stuart Foster, vice president, Global Brand Marketing, Curio Collection by Hilton. “Through our Curious Gene program, we are hoping to ignite curiosity in all people by helping them determine their next authentic travel moment at one of our more than 40 global hotels and resorts handpicked for their unique character – be it an epicurean adventure at the recently opened Lil’ B Coffee & Eatery or Siren within The Darcy Washington DC or a tranquil, beachside spa experience at the iconic Hotel del Coronado in California.”

The Science & Curiosity Types

Scientists believe that a variation of the gene, 7R, a derivative of the gene DRD4, exists in one in five people or approximately 20 percent of the human population. Through the Curious Gene study, Curio Collection by Hilton worked with a genetics lab, Fulgent Genetics, and research partner, BrandIQ, to test the 30 travel influencers to determine which of them have the “curious gene.” Each influencer also participated in a qualitative portion of the study that included a detailed online board and survey. By applying learnings from the study and leveraging existing scientific information associated with the 7R gene, researchers developed an algorithm to classify curiosity into five different types:

  • Curious Pathfinder
    • They enjoy hiking under the stars and escaping from the city lights. Their travel style is spontaneous, rustic and authentic.
  • Curious Epicurean
    • They live to eat, drink and be merry, trying almost anything on a plate or in a cup at least once. Sight, smell and taste all drive their exploration of the world and their travel is all about romance and indulgence.
  • Curious Culturalist
    • Art is everywhere, both in what they create and what they seek. For them, travel is about being stylish, passionate and open to possibilities.
  • Curious Spiritualist
    • They are always seeking the best for their inner and outer selves, and the best balance for mind and body. Their travel style is relaxed, focusing on staying grounded while being inspired, whether it be a wellness retreat or a music festival.
  • Curious Challenger
    • Their interests take them to both the rooftop and the mountaintop. Their travel style is exotic, active and well-planned.

From the initial group of influencers participating in the Curious Gene study, five who represent each curiosity type were selected to further participate in a live observational study, during which they were filmed in their natural state to further validate the categories. With remarkable hotels in some of the most sought after global destinations, Curio Collection by Hilton offers amenities to meet the desires of each curious traveler type.

So, Are You Curious?

Starting today, all wanderlusters will be able to join in the study by taking the shareable, “Are You Curious?” social media quiz to discover their curiosity type. Based on their results, participants will receive recommendations for Curio Collection by Hilton hotels and resorts that best complement their curious interests.

Curio Collection by Hilton is also part of Hilton Honors, the free to join, award-winning guest-loyalty program. Members receive instant benefits including access to the Hilton Honors app and hundreds of ways to earn and redeem Points. To live out their curiosity type, Hilton Honors members can redeem their Points for free nights, premium merchandise and just about any item on Amazon thanks to the Shop with Points program. Members can also make charitable contributions or gain access to unique events through the Hilton Honors auction platform (honors.com/auctions), such as exclusive artist experiences and concert events with Live Nation® - for the Curious Spiritualist and Culturalist, or race experiences with the McLaren-Honda Formula 1 team – for the Curious Challenger.

Consumers can continue to follow along and join the conversation with @curiocollection using the hashtag #BeCurious and visiting CitiesbyCurio.com/BeCurious for additional information. Media may access video assets, images and more at news.curio.com/BeCurious.

Research Methodology: Curio Collection by Hilton undertook a research project from June 14, 2017 through September 3rd, 2017 to understand behaviors and preferences among people who are highly engaged with travel. Firstly, using an online survey, 129 avid travelers were identified based on their travel behaviors and preferences. Following the online survey, 30 participants took part in qualitative discussions for further exploration. Concurrent to the Online Bulletin Boards, these 30 participants also provided a cheek swab that was tested to identify whether they had the DRD4-7R allele. Nine respondents tested positive for the DRD4-7R allele.

About Curio Collection by Hilton

Curio Collection by Hilton (curiocollection.com), launched in 2014, is a global portfolio of more than 40 remarkable, upper upscale hotels and resorts handpicked for their unique character and personality. Curio Collection properties appeal to travelers seeking one-of-a-kind discoveries and authentic experiences, all backed by Hilton (NYSE: HLT) and its award-winning Hilton Honors program. Read the latest Curio Collection stories at news.curiocollection.com, discover Curio Collection destinations through Cities by Curio itineraries at citiesbycurio.com and connect with the collection on facebook.com/curiocollection, instagram.com/curiocollection and twitter.com/curiocollection.

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company, with a portfolio of 14 world-class brands comprising more than 5,000 properties with over 825,000 rooms in 103 countries and territories. Hilton is dedicated to fulfilling its mission to be the world’s most hospitable company by delivering exceptional experiences – every hotel, every guest, every time. The company's portfolio includes Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio Collection by Hilton™, DoubleTree by Hilton, Tapestry Collection by Hilton™, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, Tru by Hilton, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages an award-winning customer loyalty program, Hilton Honors. Hilton Honors members who book directly through preferred Hilton channels have access to instant benefits, including a flexible payment slider that allows members to choose exactly how many Points to combine with money, an exclusive member discount that can’t be found anywhere else and free standard Wi-Fi. Visit newsroom.hilton.com for more information and connect with Hilton on FacebookTwitterLinkedInInstagram and YouTube.

Contact information

Emily Montgomery
Curio Collection by Hilton
+1 703 883 5257
Emily.Montgomery@Hilton.com
or
Jacquie Toppings
Hilton - Full Service Brands
+1 703 883 6587
Jacqueline.Toppings@Hilton.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

A Better Way to Earn Interest on Digital Assets18.1.2019 04:00Tiedote

Cred, the leading provider of crypto borrowing and lending with over $300 million in credit facilities, today announced the launch of CredEarn* on the Uphold platform. CredEarn allows Uphold customers to lend their crypto and fiat assets to Cred and receive up to 10% of annualized interest. “We’re thrilled to offer consumers the opportunity to earn interest on their digital assets and fiat currencies,” said Dan Schatt, Co-founder and President of Cred. “In a bear market, customers can benefit from the liquidity they receive when obtaining a fixed amount of interest in USD or Stablecoin. In a bull market, customers also benefit by receiving the full upside on the amount of crypto they originally committed.” CredEarn customers can commit to a six-month term with the ability to rollover assets for additional periods. No account minimum is needed and interest is paid out in U.S. Dollars or Stablecoin every three months on Uphold. The principal is paid back in the fiat or crypto amounts tha

Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)18.1.2019 02:45Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today that the safety and efficacy data in the gastrectomy patient subgroup of the global Phase III trial TAGS evaluating LONSURF® (trifluridine/tipiracil, TAS-102) in patients with metastatic gastric cancer (mGC) are consistent with the overall study results published in The Lancet Oncology. These data were highlighted in an oral presentation at the ASCO 2019 Gastrointestinal Cancers Symposium (ASCO-GI) on Thursday 17 January. In TAGS, 221 (44%) of the 507 randomized mGC patients had undergone prior gastrectomy (147 LONSURF, 74 placebo), which is reflective of the real-world patient population diagnosed with mGC. The results confirmed that trifluridine/tipiracil prolonged survival versus placebo regardless of prior gastrectomy. The overall results of TAGS demonstrated that patients treated with oral trifluridine/tipiracil showed a clinically meaningful and statistically s

ISACA Announces 2019 Slate of Events for Business Technology Professionals Around the Globe During its 50th Anniversary Year17.1.2019 22:24Tiedote

ISACA, a global association serving technology audit, assurance, governance and cybersecurity professionals, celebrating its 50th anniversary in 2019, announced its annual event schedule, which includes learning opportunities focused on emerging technologies, innovation, best practices and professional development. Disruptive technologies over the last 50 years and in the future of business enterprise, and the evolution of technology careers and ISACA professions, will be featured in conjunction with the ISACA anniversary year at nearly every venue. ISACA’s growing Cybersecurity Solution Portfolio, including the CSX Training Platform and the CMMI Cybermaturity Platform, will be highlighted in new conferences in 2019, which will include events in North America and Europe. The 2019 CACS conferences, set for North America, Europe, Asia, Africa, the Oceania region and Latin America, will offer educational sessions in audit and assurance, big data, risk management, governance and more. All

HighLife Closes a €32 Million Round B Financing17.1.2019 20:25Tiedote

HighLife SAS, a medtech company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, announced today it had closed a €32 million round of equity financing. Proceeds from the financing will be used to complete the development of the company’s transcatheter transseptal mitral valve implantation program, which includes regulatory approval trials in Europe to obtain the CE mark and a first clinical trial in the U.S. via an Early Feasibility Study (EFS). The Series B round was co-led by U.S. Venture Partners (“USVP”) and Andera Partners, with Sectoral Asset Management and Jose Calle Gordo, Chairman of the company, joining the round. Sofinnova Partners, which led the Series A round, continues to support the company and participated in this latest round of financing. Bryan Garnier & Co (Paris) acted as private placement agent for this financing. “I am very pleased to announce the closing of the Ser

The Brightline™ Initiative, led by Project Management Institute, to Support The Economist Davos Panel17.1.2019 18:00Tiedote

The Brightline™ Initiative, a coalition dedicated to helping executives bridge the gap between strategy design and delivery, along with Project Management Institute is hosting The Economist Events panel discussion entitled “Humans 2.0: Designing and Implementing a Future Proof Strategy.” In line with Davos’ overarching theme, “Globalization 4.0: Shaping a Global Architecture in the Age of the Fourth Industrial Revolution,” panelists will discuss how business leaders can harness the power of people to adapt and implement corporate strategies and grapple with the effects of disruptive technologies. This topic is of particular interest to PMI, the leading member of Brightline, given how this wave of disruption calls for organizations to rely on successful implementation of new strategies at unprecedented scope and speed to meet market demands. “As a coalition committed to moving from idea to strategy implementation to results, we’re delighted to partner with The Economist Events to bring

MSCI Schedules Investor Conference Call to Review Fourth Quarter and Full Year 2018 Results17.1.2019 17:00Tiedote

MSCI Inc. (NYSE:MSCI), a leading provider of indexes and portfolio construction and risk management tools and services for global investors, today announced it will release its results for the fourth quarter and full year 2018 on Thursday, January 31, 2019. MSCI's senior management will review the fourth quarter and full year 2018 results on Thursday, January 31, 2019 at 11:00 AM Eastern Time. To listen to the live event, visit the events and presentations section of MSCI's Investor Relations homepage, http://ir.msci.com/events.cfm, or dial 1-877-376-9931 conference ID: 3474708 within the United States. International callers dial 1-720-405-2251 conference ID: 3474708. The earnings release and related investor presentation used during the conference call will be made available on MSCI's Investor Relations homepage. An audio recording of the conference call will be available on our Investor Relations website, http://ir.msci.com/events.cfm, beginning approximately two hours after the conc

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme